Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.76 |
| ▸ | HTR1A | P08908 | 12/20 | 0.76 |
| ▸ | HTR2A | P28223 | 6/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7543848 | 0.86 | HTR1A (1.00) | DRD2HTR1AHTR2AHTTOPRM1 | |
| SCHEMBL1719942 | 0.85 | KDM4E (0.74) | DRD2HTR1AHTR2AHTTKDM4E | |
| SCHEMBL8723512 | 0.82 | DRD2 (0.67) | DRD2HTR1AHTR2AHTTOPRM1 | |
| SCHEMBL5803833 | 0.79 | DRD2 (0.63) | DRD2HTR1AHTR2AHTTOPRM1 | |
| SCHEMBL4810830 | 0.79 | PARP1 (0.53) | DRD2HTR1AHTR2AHTTOPRM1 | |
| SCHEMBL14280720 | 0.79 | OPRM1 (1.00) | DRD2HTR1AHTR2AHTTOPRM1 | |
| SCHEMBL13944353 | 0.78 | DRD2 (0.79) | DRD2HTR1AHTR2AHTTOPRM1 | |
| SCHEMBL4817530 | 0.78 | PARP1 (0.53) | DRD2HTR1AHTR2AHTTOPRM1 | |
| SCHEMBL9527241 | 0.78 | OPRM1 (0.78) | DRD2HTR1AHTR2AHTTOPRM1 | |
| SCHEMBL7536094 | 0.78 | OPRM1 (0.78) | DRD2HTR1AHTR2AHTTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | claimed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | claimed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | claimed |
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | DRD2 3406/4885HTR1A 2300/4885HTR2A 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.